238 related articles for article (PubMed ID: 25157764)
1. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.
Carlsson A; Nair VS; Luttgen MS; Keu KV; Horng G; Vasanawala M; Kolatkar A; Jamali M; Iagaru AH; Kuschner W; Loo BW; Shrager JB; Bethel K; Hoh CK; Bazhenova L; Nieva J; Kuhn P; Gambhir SS
J Thorac Oncol; 2014 Aug; 9(8):1111-9. PubMed ID: 25157764
[TBL] [Abstract][Full Text] [Related]
2. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.
Nair VS; Keu KV; Luttgen MS; Kolatkar A; Vasanawala M; Kuschner W; Bethel K; Iagaru AH; Hoh C; Shrager JB; Loo BW; Bazhenova L; Nieva J; Gambhir SS; Kuhn P
PLoS One; 2013; 8(7):e67733. PubMed ID: 23861795
[TBL] [Abstract][Full Text] [Related]
3. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
4. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Bian J; Yan K; Liu N; Xu X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
[TBL] [Abstract][Full Text] [Related]
5. Multiblock Discriminant Analysis of Integrative
Lee SH; Kao GD; Feigenberg SJ; Dorsey JF; Frick MA; Jean-Baptiste S; Uche CZ; Cengel KA; Levin WP; Berman AT; Aggarwal C; Fan Y; Xiao Y
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1451-1465. PubMed ID: 33662459
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC.
Mascalchi M; Falchini M; Maddau C; Salvianti F; Nistri M; Bertelli E; Sali L; Zuccherelli S; Vella A; Matucci M; Voltolini L; Pegna AL; Luconi M; Pinzani P; Pazzagli M
J Cancer Res Clin Oncol; 2016 Jan; 142(1):195-200. PubMed ID: 26210156
[TBL] [Abstract][Full Text] [Related]
8. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
9. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.
Mattes MD; Moshchinsky AB; Ahsanuddin S; Rizk NP; Foster A; Wu AJ; Ashamalla H; Weber WA; Rimner A
Clin Lung Cancer; 2015 Nov; 16(6):e253-8. PubMed ID: 26163919
[TBL] [Abstract][Full Text] [Related]
10. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
11. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.
Wendel M; Bazhenova L; Boshuizen R; Kolatkar A; Honnatti M; Cho EH; Marrinucci D; Sandhu A; Perricone A; Thistlethwaite P; Bethel K; Nieva J; Heuvel Mv; Kuhn P
Phys Biol; 2012 Feb; 9(1):016005. PubMed ID: 22307026
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
Manjunath Y; Upparahalli SV; Suvilesh KN; Avella DM; Kimchi ET; Staveley-O'Carroll KF; Li G; Kaifi JT
Lung Cancer; 2019 Aug; 134():147-150. PubMed ID: 31319973
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
Duan XY; Wang W; Wang JS; Shang J; Gao JG; Guo YM
BMC Cancer; 2013 Nov; 13():546. PubMed ID: 24237755
[TBL] [Abstract][Full Text] [Related]
14. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
[TBL] [Abstract][Full Text] [Related]
15. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
[TBL] [Abstract][Full Text] [Related]
16. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.
Hyun SH; Ahn HK; Kim H; Ahn MJ; Park K; Ahn YC; Kim J; Shim YM; Choi JY
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):50-8. PubMed ID: 23948859
[TBL] [Abstract][Full Text] [Related]
17. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer:
Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F
J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
20. Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non-small-cell lung cancer manifesting as a subsolid nodule.
Lee SM; Park CM; Paeng JC; Im HJ; Goo JM; Lee HJ; Kang CH; Kim YW; Kim JI
Eur Radiol; 2012 Jul; 22(7):1556-63. PubMed ID: 22358427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
